Fulcrum Therapeutics(FULC)
CAMBRIDGE, MA
Biotechnology1 H-1B visas (FY2023)Focus: Unlocking gene control mechanisms to develop small molecule therapies
Fulcrum Therapeutics is a life sciences company focused on Unlocking gene control mechanisms to develop small molecule therapies.
Rare DiseasesHematologyInfectious Diseases
Funding Stage
PUBLIC
Total Funding
$150M
Open Jobs
3
Pipeline & Clinical Trials
Pociredir oral capsule
Sickle Cell DiseaseClinical Trials (1)
NCT05169580Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
Phase 1FTX-6058/placebo oral capsule
Healthy Adult SubjectsClinical Trials (1)
NCT04586985Safety, Tolerability and Pharmacokinetics of FTX-6058
Phase 1Losmapimod 15 mg oral tablet
Healthy Adult SubjectsClinical Trials (1)
NCT05002231Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets
Phase 1Pociredir
Sickle Cell DiseaseClinical Trials (1)
NCT07431398Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
Phase 1ACE393
Campylobacter InfectionClinical Trials (1)
NCT00859716ACE393-103 Vaccination Challenge Study
Phase 2Losmapimod
Facioscapulohumeral Muscular Dystrophy 1Clinical Trials (1)
NCT04004000Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension
Phase 2Phase 2
Clinical Trials (1)
NCT04264442Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)
Phase 2Losmapimod oral tablet
Facioscapulohumeral Muscular Dystrophy (FSHD)Clinical Trials (1)
NCT04003974Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase 2Pociredir
Sickle Cell DiseaseClinical Trials (1)
NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101
Phase 2Losmapimod oral tablet
COVID-19Clinical Trials (1)
NCT04511819Losmapimod Safety and Efficacy in COVID-19
Phase 3Phase 3
Clinical Trials (1)
NCT05397470Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
Phase 3Open Jobs (3)
Interview Prep Quick Facts
Founded: 2011
Portfolio: 11 clinical trials
H-1B (2023): 1 approval
SEC Filings: 2 available
Open Roles: 3 active jobs
Financials (FY2025)
Revenue
$80M2752%
R&D Spend
$63M(79%)12%
Net Income
-$10MCash
$58MHiring Trend
Stable
3
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub